Cibus, Inc. (CBUS)
NASDAQ: CBUS · Real-Time Price · USD
2.055
-0.025 (-1.20%)
At close: Feb 9, 2026, 4:00 PM EST
2.050
-0.005 (-0.24%)
After-hours: Feb 9, 2026, 6:32 PM EST
Cibus Revenue
Cibus had revenue of $615.00K in the quarter ending September 30, 2025, a decrease of -63.11%. This brings the company's revenue in the last twelve months to $3.79M, down -8.64% year-over-year. In the year 2024, Cibus had annual revenue of $4.26M with 134.56% growth.
Revenue (ttm)
$3.79M
Revenue Growth
-8.64%
P/S Ratio
21.12
Revenue / Employee
$23,862
Employees
159
Market Cap
138.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.26M | 2.45M | 134.56% |
| Dec 31, 2023 | 1.82M | 1.66M | 1,057.32% |
| Dec 31, 2022 | 157.00K | -25.83M | -99.40% |
| Dec 31, 2021 | 25.99M | 2.14M | 8.96% |
| Dec 31, 2020 | 23.85M | 16.56M | 226.91% |
| Dec 31, 2019 | 7.30M | 7.06M | 2,991.53% |
| Dec 31, 2018 | 236.00K | -272.00K | -53.54% |
| Dec 31, 2017 | 508.00K | 109.00K | 27.32% |
| Dec 31, 2016 | 399.00K | -873.00K | -68.63% |
| Dec 31, 2015 | 1.27M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vaxart | 148.20M |
| Spero Therapeutics | 40.55M |
| Caribou Biosciences | 9.30M |
| Oramed Pharmaceuticals | 2.00M |
| Connect Biopharma Holdings | 762.00K |
CBUS News
- 3 days ago - Cibus Partnering with The John Innes Centre for UK Government's Farming Innovation Programme Precision Breeding Initiative - GlobeNewsWire
- 11 days ago - Cibus, Inc. Announces Pricing of $20.0 Million Public Offering of Class A Common Stock - GlobeNewsWire
- 12 days ago - Cibus, Inc. Announces Proposed Public Offering of Class A Common Stock - GlobeNewsWire
- 5 weeks ago - Cibus and Interoc Advance Rice Commercialization Strategy for Herbicide-Tolerant Traits in Key Markets across Latin America - GlobeNewsWire
- 2 months ago - Cibus Welcomes the Positive Conclusion of Trilogue Negotiations on New Genomic Techniques Legislation Between the European Parliament and Council - GlobeNewsWire
- 3 months ago - Cibus, Inc. (CBUS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Cibus Reports Third Quarter Financial Results and Provides Year-to-Date Business Update for 2025 - GlobeNewsWire
- 3 months ago - Cibus Announces the Election of Craig Wichner to Board of Directors - GlobeNewsWire